An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Hydrolysis of avibactam and aztreonam by NDM-1. (A) Structures of avibactam and aztreonam.…
FIG 1
Hydrolysis of avibactam and aztreonam by NDM-1. (A) Structures of avibactam and aztreonam. (B) Extent of aztreonam (100 μM) hydrolysis by VIM-4, BcII, and NDM-1 (all 10 μM) after 16 h. Hydrolysis was monitored by NMR spectroscopy (700 MHz); the peaks labeled with an asterisk correspond to the aztreonam proton indicated with an asterisk in panel A, while the peaks labeled with two asterisks indicate the hydrolyzed product. (C) Extent of hydrolysis of a mixture of aztreonam (ATM; 1 mM) and avibactam (AVI; 1 mM) by NDM-1 (10 μM) after 50 min with 100 μM ZnCl2–50 mM Tris-d11 (pH 7.5)–10% D2O. The addition of d-captopril (500 μM) or EDTA (2 mM) or removal of ZnCl2 inhibited aztreonam hydrolysis. (D) Preliminary kinetic characterization of avibactam and aztreonam hydrolysis by NDM-1 as monitored by NMR and UV-Vis analysis. The NMR studies used 10 μM NDM-1, 100 μM ZnCl2, and the indicated concentration of avibactam or aztreonam in 50 mM Tris-d11 (pH 7.5)–10% D2O. The UV-Vis studies (monitored at 230 nm) used 10 μM NDM-1, 20 μM ZnCl2, and the indicated concentration of avibactam in 5 mM HEPES, pH 7.5 (2). Nonlinear regression analyses were performed using Prism 7 (GraphPad). (E and F) Hydrolysis of (E) aztreonam and (F) avibactam by a panel of β-lactamases covering classes A (black), B (red), C (blue), and D (green). Hydrolysis was measured by NMR after 24 h for samples consisting of enzyme (10 μM) and avibactam (400 μM) or aztreonam (1 mM) in 50 mM Tris-d11 (pH 7.5)–10% D2O.
Prosperi-Meys C, Llabres G, de Seny D, Soto RP, Valladares MH, Laraki N, Frere JM, Galleni M. 1999. Interaction between class B β-lactamases and suicide substrates of active-site serine β-lactamases. FEBS Lett 443:109–111. doi: 10.1016/S0014-5793(98)01689-5.
-
DOI
-
PubMed
Abboud MI, Damblon C, Brem J, Smargiasso N, Mercuri P, Gilbert B, Rydzik AM, Claridge TD, Schofield CJ, Frère JM. 2016. Interaction of avibactam with class B metallo-β-lactamases. Antimicrob Agents Chemother 60:5655–5662. doi: 10.1128/AAC.00897-16.
-
DOI
-
PMC
-
PubMed
Fernandes P, Martens E. 2017. Antibiotics in late clinical development. Biochem Pharmacol 133:152–163. doi: 10.1016/j.bcp.2016.09.025.
-
DOI
-
PubMed
Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K. 1989. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 33:1451–1456. doi: 10.1128/AAC.33.9.1451.
-
DOI
-
PMC
-
PubMed
Walsh TR. 2005. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria. Clin Microbiol Infect 11(Suppl 6):2–9. doi: 10.1111/j.1469-0691.2005.01264.x.
-
DOI
-
PubMed